首页 / 院系成果 / 成果详情页

Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone 期刊论文

编号：

04fe090d-a11c-40d9-bd51-b7b657ecf843
作者：

Xu, Binghe^[1,2];Guan, Zhongzhen^[3];Shen, Zhenzhou(沈镇宙)^[4]Tong, Zhongshen^[5];Jiang, Zefei^[6];Yang, Junlan^[7];DeSilvio, Michelle^[8];Russo, Mark^[8];Leigh, Meggan^[8];Ellis, Catherine^[8];
语种：

英文
期刊：

BREAST CANCER RESEARCH ISSN：1465-542X 2014 年 16 卷 4 期
收录：
摘要：

Introduction: Phosphatidylinositol 3-kinase (PI3K) pathway deregulation (that is PIK3CA mutations and/or phosphatase and tensin homolog (PTEN) loss) has been shown to enhance breast cancer cell survival and confer resistance to chemotherapeutic agents. We studied the prognostic and predictive value of PIK3CA mutations and PTEN low in patients receiving paclitaxel alone or in combination with lapatinib.
Methods: Immunohistochemistry and mutation analyses were used to evaluate PTEN and PIK3CA, respectively. Kaplan-Meier analysis with log-rank tests, logistic regression and Cox models were used in analyses of these biomarkers with efficacy endpoints.
Results: In the overall population, PIK3CA mutations were associated with poorer overall survival (OS) (hazard ratio (HR) = 1.87; 95% confidence interval (CI): 1.22, 2.88; P = 0.001). PTEN expression was not associated with OS (P = 0.474). In the PIK3CA wild-type subgroup, lapatinib plus paclitaxel reduced risk of progression compared with paclitaxel alone (HR = 0.44; 95% CI: 0.28, 0.69; P <0.0001); progression-free survival (PFS) was not significantly improved within the PIK3CA mutation subgroup (P = 0.179). In the PTEN low group, OS was improved with addition of lapatinib (P = 0.039). In both PTEN subgroups, addition of lapatinib was associated with improvements in PFS (P <0.050). PIK3CA and PTEN were not predictive of treatment based on interaction tests (P >0.05).
Conclusions: PTEN was neither a significant prognostic nor predictive factor. PIK3CA mutations were an adverse prognostic factor for survival but not predictive for lapatinib benefit.
推荐引用方式
GB/T 7714：

Xu Binghe,Guan Zhongzhen,Shen Zhenzhou, et al. Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone [J].BREAST CANCER RESEARCH,2014,16(4).
APA：

Xu Binghe,Guan Zhongzhen,Shen Zhenzhou,Tong Zhongshen,&Ellis Catherine.(2014).Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone .BREAST CANCER RESEARCH,16(4).
MLA：

Xu Binghe, et al. "Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone" .BREAST CANCER RESEARCH 16,4(2014).
条目包含文件：

文件类型：PDF,文件大小：

正在加载全文

未找到全文

浏览次数：4  下载次数：0

分享到：

浏览次数：4

下载次数：0

打印次数：0